Patrick Tricoli joins Hemerion as “Strategy & Corporate Development Senior Advisor”

Patrick Tricoli, PharmD, MBA, a long-time Boston resident, is joining our team as Senior Advisor for Strategy & Corporate Development.
He brings his in-depth knowledge of the U.S. market and unique perspective on business development to Hemerion. These assets are essential for accelerating our expansion in the U.S. and forging new strategic partnerships.

Patrick Tricoli, a senior executive and healthcare industry specialist in the U.S., previously led Nanobiotix’s U.S. subsidiary and business development efforts. In that role, he orchestrated the partnership between Nanobiotix and J&J, valued at over $2 billion.

Having long headed Sanofi’s international R&D partnerships, Tricoli is deeply familiar with the challenges facing healthtech and biotech startups. He has advised several major players, including Naya Biosciences, NanOlogy, Curadigm, and Rest Therapeutics, at the highest level.

Patrick  is also a French  Foreign Trade Advisor (CCE) in Boston/New England and heads a group of experts on investment flows between the United States and France in the biotechnology and healthcare sectors.

Based in Boston, Patrick Tricoli will be responsible for leading Hemerion’s expansion in the U.S. market. He brings a unique combination of expertise, blending a strong scientific background in neuroscience (gained at Lederle and Synthelabo) with proven experience in global business development.

“Throughout my career, I have rarely encountered a technology as elegant and clinically effective as Hemerion’s combination therapy for treating glioblastoma. I am convinced that this therapy has the potential to be a game-changer, not only for brain cancer treatment, but also for treating other solid tumors. My goal is to integrate this technology into the standard of care for glioblastoma in the U.S. and foster its global development for other forms of cancer.“